Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 6/1999

Content (8 Articles)

ORIGINAL PAPER

The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer

Maurizio Setti, Donatella Bignardi, Alberto Ballestrero, Fabio Ferrando, Cristina Musselli, Sabrina Blanchi, Monica Basso, Ornella Bosco, Enrico Balleari, Franco Patrone, Francesco Indiveri

ORIGINAL ARTICLE

An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy

Pamela M. J. McLaughlin, Bart-Jan Kroesen, Wim H. A. Dokter, Henk van der Molen, Martijn de Groot, Marja G.L. Brinker, Klaas Kok, Marcel H. J. Ruiters, Charles H. C. M. Buys, Lou F. M. H. de Leij

ORIGINAL ARTICLE

Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model

Kazuki Yamanaka, Isao Hara, Hiroshi Nagai, Hideaki Miyake, Kazuo Gohji, Mark J. Micallef, Masashi Kurimoto, Soichi Arakawa, Sadao Kamidono

ORIGINAL ARTICLE

Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells

Peter Jantscheff, Richard Herrmann, Giulio Spagnoli, Jürgen Reuter, Majid Mehtali, Michael Courtney, Christoph Rochlitz

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine